ArticleEMBO molecular medicine2024
Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer.
Article in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Preoperative clinical-imaging nomogram for peritoneal metastasis in gastric cancer: a retrospective cohort study.BMC gastroenterology · 2026Article
- Comparative analysis of the transcriptome and methylome in distinct trophoblast populations at the time of embryo implantation in mares.BMC genomics · 2026Article
- The FOXC2-LAMA4 Axis Orchestrates Vasculogenic Mimicry and Immunosuppressive Niche Formation to Drive Metastatic Cascade in Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Modulating tumor-associated macrophages through APP-CD74 blockade with IL4R-exosomes synergizes with PD-1 inhibition in gastric cancer.NPJ precision oncology · 2026Article
- M2 polarization of macrophage induced by IL-33 promotes mouse sciatic nerve regeneration.Cell & bioscience · 2026Article
- Immune modulation in gastric cancer: from macrophage polarization to immunotherapy.Frontiers in immunology · 2026Review
- Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA.Theranostics · 2026Article
- POSTNFrontiers in immunology · 2026Article
- Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance.Frontiers in immunology · 2026Review
- Etoposide activates CD8Journal for immunotherapy of cancer · 2025Article
- Absence of BCAP in myeloid cells abrogates M2 macrophage differentiation and promotes anti-tumor immunity.iScience · 2025Article
- Unlocking IL-33: New Insights into Tumor Immunity.Immune network · 2025Review
- Machine Learning-Driven SERS Analysis Platform for Accurate and Rapid Diagnosis of Peritoneal Metastasis from Gastric Cancer.Annals of surgical oncology · 2025Article
- ARID1A mutation drives gastric tumorigenesis via activating type 2 immune dominant microenvironment.iScience · 2025Article
- Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Peritoneal resident macrophages constitute an immunosuppressive environment in peritoneal metastasized colorectal cancer.Nature communications · 2025Article
- The artificial intelligence revolution in gastric cancer management: clinical applications.Cancer cell international · 2025Review
- Signature Construction Associated with Tumor-Infiltrating Macrophages Identifies IRF8 as a Novel Biomarker for Immunotherapy in Advanced Gastric Cancer.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Peritoneal metastasis (PM) has a suppressive tumor immune microenvironment (TIME) that limits the effects of immunotherapy. This study aimed to investigate the immunomodulatory effects of intraperitoneal administration of IL-33, a cytokine that is reported to potentiate antitumor immunity and inhibit metastasis. We found survival was significantly prolonged in patients with high IL-33 mRNA expression. In immunocompetent mice, intraperitoneal administration of IL-33 could induce a celiac inflammatory environment, activate immunologic effector cells, and reverse the immunosuppressive tumor microenvironment, which effectively delayed tumor progression and PM of gastric cancer. Mechanistically, IL-33 could induce M2 polarization by activating p38-GATA-binding protein 3 signaling. IL-33 combined with anti-CSF1R or p38 inhibitor to regulate tumor-associated macrophages (TAMs) had a synergistic antitumor effect. Inducing a local inflammatory milieu by IL-33 administration provided a novel approach for treating peritoneal metastasis, which, when combined with TAM reprogramming to reshape TIME, can achieve better treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.